No abstract

No abstract

No abstract

statistical difference between groups (p=0.05). The mean of UMAC was 1258.92AE765.19 pg/ml, with significant differences between the groups; although, no differences were found in the UMAC levels with to the degree of fibrosis (p= 0.10), subjects without fibrosis had the lowest levels of UMAC (770.1AE579 vs 1680.31AE490.1 severe fibrosis). The 100% of patients received induction treatment with corticosteroids, 88% ACEI, 84% statins, 16% steriods+CNi, 8% calcium channel blockers. The basal UMAC levels were lower in those subjects with complete response to treatment, with differences between the groups (p= 0.003). UMAC had significant correlation with final proteinuria (r=0.5, p=0.01) and CKD-EPI (r=-0.6, p=0.002). Figure 1 Conclusions: The membrane attack complex represents the final stage of activation of the complement system (C5b-9). Our results showed that high levels of UMAC in patients with FSGF with a statistical correlation, had the worst histological varieties. The patients who had the benign varieties (lower UMAC levels), responded better to treatment, inferring that UMAC could be a prognosis biomarker for treatment response, however, these results must be confirmed with a higher number of patients in prospective cohort methodological studies.

KT patients were divided in two groups: aKT and non-aKT. Assisted KT patients were defined as dependent patients whose physical or cognitive deficits preclude them to take full responsibility for their care and medication. All 25 patients who were under aKT program where included and a comparative analysis regarding graft failure, all-cause mortality, and combined event (graft failure or death) between both groups was done. Results: Of the 1503 kidney transplants performed during the study period, follow-up was lost in 27 (1.8%). Twenty six KT (1.7%) were performed in 25 patients eligible for inclusion as aKT. At the time of the analysis, 25 (96.2%) of this aKT maintained a functioning graft; the only lost graft was due to chronic rejection 32 months after the first KT in a 13 years old recipient, who subsequently received a second kidney transplant. Dependence causes of aKT patients were: cognitive deficits 18 (72%), blindness 3 (12%), illiteracy 2 (8%) and childwood 2 (8%). Comparing aKT versus non-aKT: 13 (50%) vs 911 pts (62.8%) were male (p = 0.180), the median age at the time of transplantation was 35.8 AE 19.5 years vs 45.2 AE 14.1 years (p = 0.001), the mean follow-up was 10.0 AE 7.2 years vs 8.9 AE 6.5 years (p = 0.445) and 1 (3.8%) vs 361 pts (24.9%) evolved to graft failure (p = 0.010). All cause mortality was observed in 0 (0%) vs 246 pts (17.0%) (p = 0.014) and the combined event was seen in 1 (3.8%) versus 607 patients (41.9%) (p < 0.001). Using Kaplan-Meier analysis, the comparison of both groups revealed a statistically significant difference regarding the graft failure (p = 0.021) and combined event (p = 0.001). Adjusting for age, aKT showed a lower prevalence of both graft failure (p = 0.022) and combined event (p = 0.017). Conclusions: Despite the limited number of patients, our results unveiled non-inferior outcomes in aKT patients. This makes aKT an opportune, reliable and effective alternative for renal replacement therapy in disabled patients. Muldisciplinary assessment of the assistant care provider may be a key step for the success of this program. Further studies are required, especially those including relevant pre and post-transplant clinical data related to graft and patient survival.